Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s-Reference-Cited by-同舟云学术

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

Published:2013-08-15 Issue:7 Volume:122 Page:1129-1136
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Fischer Kathelijn¹²,Steen Carlsson Katarina³,Petrini Pia⁴⁵,Holmström Margareta⁵,Ljung Rolf⁶⁷,van den Berg H. Marijke²,Berntorp Erik³⁷

Affiliation:

1. Van Creveldkliniek, Department of Hematology and

2. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands;

3. Department of Clinical Sciences, Malmö, Lund University, Skåne University Hospital, Malmö, Sweden;

4. Department of Paediatrics and

5. Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden;

6. Lund University, Department of Paediatrics, Malmö/Lund, Sweden; and

7. Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden

Abstract

Key Points Compared with intermediate-dose prophylaxis (3 × 1000 IU/wk), high-dose prophylaxis (3 × 2000 IU/wk) resulted in a 66% higher total cost. At age 24 years, high-dose prophylaxis resulted in a small reduction in bleeding and hemophilic arthropathy, but equal quality of life.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/7/1129/1373906/1129.pdf

Reference49 articles.

1. Haemophilia prophylaxis in Sweden.;Nilsson;Acta Paediatr Scand,1976

2. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B.;Nilsson;J Intern Med,1992

3. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy.;Fischer;Haemophilia,2001

4. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.;Steen Carlsson;Haemophilia,2003

5. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.;Khawaji;Eur J Haematol,2012

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS);Thrombosis Research;2024-09

2. Coagulation protease–induced extracellular vesicles: their potential effects on coagulation and inflammation;Journal of Thrombosis and Haemostasis;2024-08

3. Report on the diagnosis and treatment of hemophilia in China (Version 2024);LabMed Discovery;2024-07

4. Patient Perspective on Disease Burden and Gene Therapy for Hemophilia A and B: The “Haemvolution for Patients” Italian Survey;Seminars in Thrombosis and Hemostasis;2024-06-18

5. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients;Haemophilia;2024-05-13